

Health Research at a Crossroads – Are Public-Private Partnerships the Way Forward?

European Parliament, Brussels – 13 November 2012

Room PHS P7C050

17:00 – 20:00

16:00 - 17:00

Registration

17:00 – 18:00

Introducing IMI

Welcome and introduction

Amalia Sartori MEP

IMI – created for patients, for researchers, for industry

Françoise Grossetête MEP

IMI – the story so far

Ruxandra Draghia-Akli, European Commission

IMI's added value to the pharmaceutical industry

Roch Doliveux, Chair of the IMI Governing Board

18:00 - 18:20

Break

18:20 – 20:00

Panel discussion

Health research is at a crossroads. Developing new drugs for the many diseases and conditions that still lack a cure or effective treatment is proving extremely difficult, leading some pharmaceutical companies to give up on entire disease areas. Meanwhile, budgets for drug research and development are tighter than ever. Are public-private partnerships (PPPs) the way forward? Or would other models offer a better solution?

Moderator

Andrew Jack, Financial Times

Panellists

Michel Goldman, Executive Director, IMI

Ruxandra Draghia-Akli, European Commission

Richard Bergström, EFPIA

Mary Baker, European Brain Council

Rolf-Detlef Treede, University of Heidelberg

Tine Bryan Stensbøl, Lundbeck

Hans-Georg Eichler, European Medicines Agency

Scott Wagers, BioSci Consulting

20:00

End of meeting

20:00

Networking reception

This event is kindly hosted by Ms Amalia Sartori MEP